(ROP) Roper Technologies - Overview
Stock: Software, Analytics, Payment, Metering, Medical
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.68% |
| Yield on Cost 5y | 0.86% |
| Yield CAGR 5y | 10.02% |
| Payout Consistency | 97.1% |
| Payout Ratio | 16.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.5% |
| Relative Tail Risk | 2.13% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.01 |
| Alpha | -48.43 |
| Character TTM | |
|---|---|
| Beta | 0.613 |
| Beta Downside | 0.693 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.87% |
| CAGR/Max DD | -0.12 |
Description: ROP Roper Technologies January 27, 2026
Roper Technologies, Inc. (NASDAQ: ROP) creates and sells vertical-market software and technology-enabled hardware across North America, Europe, and Asia, serving industries such as healthcare, education, insurance, and industrial automation.
The business is organized into three segments: (1) **Application Software**, which delivers cloud-based management, diagnostic, and financial analytics solutions-including K-12 administration, transportation, and property-casualty insurance platforms; (2) **Network Software**, offering data-collaboration, estimating automation, visual-effects, supply-chain, and pharmacy software; and (3) **Technology-Enabled Products**, providing medical devices, precision measurement systems, RFID readers, and related hardware. Distribution is a mix of direct sales, reps, and channel partners.
In FY 2025 Roper reported **$7.1 billion in revenue**, a **8 % year-over-year increase**, and **adjusted EPS of $5.23**, reflecting an operating margin of roughly **15 %**. The company’s growth has been driven by continued demand for SaaS solutions in healthcare and insurance (sector SaaS spend grew ~12 % YoY in 2025) and by expanding automation in industrial water-meter and sensor markets, which have seen a **4-year compound annual growth rate (CAGR) of 9 %**. Recent acquisitions-including the 2024 purchase of a cloud-based compliance platform for $420 million-have added roughly **$250 million** of recurring revenue to the Application Software segment.
For a deeper quantitative comparison of ROP’s valuation metrics against peers, the ValueRay platform offers a concise dashboard worth checking.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 1.54b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.16 > 1.0 |
| NWC/Revenue: -22.75% < 20% (prev -32.53%; Δ 9.78% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.52b > Net Income 1.54b |
| Net Debt (-297.4m) to EBITDA (3.13b): -0.09 < 3 |
| Current Ratio: 0.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (107.8m) vs 12m ago -0.28% < -2% |
| Gross Margin: 69.24% > 18% (prev 0.69%; Δ 6855 % > 0.5%) |
| Asset Turnover: 23.98% > 50% (prev 22.46%; Δ 1.51% > 0%) |
| Interest Coverage Ratio: 5.03 > 6 (EBITDA TTM 3.13b / Interest Expense TTM 325.0m) |
Altman Z'' 2.84
| A: -0.05 (Total Current Assets 1.93b - Total Current Liabilities 3.73b) / Total Assets 34.58b |
| B: 0.50 (Retained Earnings 17.21b / Total Assets 34.58b) |
| C: 0.05 (EBIT TTM 1.63b / Avg Total Assets 32.96b) |
| D: 1.16 (Book Value of Equity 17.11b / Total Liabilities 14.70b) |
| Altman-Z'' Score: 2.84 = A |
Beneish M -3.00
| DSRI: 0.97 (Receivables 1.12b/1.04b, Revenue 7.90b/7.04b) |
| GMI: 1.00 (GM 69.24% / 69.30%) |
| AQI: 0.99 (AQ_t 0.94 / AQ_t-1 0.95) |
| SGI: 1.12 (Revenue 7.90b / 7.04b) |
| TATA: -0.03 (NI 1.54b - CFO 2.52b) / TA 34.58b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = A |
What is the price of ROP shares?
Over the past week, the price has changed by -2.37%, over one month by -16.98%, over three months by -18.29% and over the past year by -37.47%.
Is ROP a buy, sell or hold?
- StrongBuy: 10
- Buy: 2
- Hold: 6
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the ROP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 462.2 | 27.5% |
| Analysts Target Price | 462.2 | 27.5% |
| ValueRay Target Price | 301.7 | -16.8% |
ROP Fundamental Data Overview February 01, 2026
P/E Forward = 26.3852
P/S = 5.0564
P/B = 2.7273
P/EG = 2.5891
Revenue TTM = 7.90b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 3.13b USD
Long Term Debt = 9.15b USD (from longTermDebt, two quarters ago)
Short Term Debt = 300.0m USD (from shortTermDebt, two quarters ago)
Debt = 9.45b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -297.4m USD (from netDebt column, last quarter)
Enterprise Value = 49.11b USD (39.96b + Debt 9.45b - CCE 297.4m)
Interest Coverage Ratio = 5.03 (Ebit TTM 1.63b / Interest Expense TTM 325.0m)
EV/FCF = 19.96x (Enterprise Value 49.11b / FCF TTM 2.46b)
FCF Yield = 5.01% (FCF TTM 2.46b / Enterprise Value 49.11b)
FCF Margin = 31.13% (FCF TTM 2.46b / Revenue TTM 7.90b)
Net Margin = 19.44% (Net Income TTM 1.54b / Revenue TTM 7.90b)
Gross Margin = 69.24% ((Revenue TTM 7.90b - Cost of Revenue TTM 2.43b) / Revenue TTM)
Gross Margin QoQ = 69.46% (prev 69.54%)
Tobins Q-Ratio = 1.42 (Enterprise Value 49.11b / Total Assets 34.58b)
Interest Expense / Debt = 0.99% (Interest Expense 93.3m / Debt 9.45b)
Taxrate = 19.87% (106.2m / 534.6m)
NOPAT = 1.31b (EBIT 1.63b * (1 - 19.87%))
Current Ratio = 0.52 (Total Current Assets 1.93b / Total Current Liabilities 3.73b)
Debt / Equity = 0.48 (Debt 9.45b / totalStockholderEquity, last quarter 19.88b)
Debt / EBITDA = -0.09 (Net Debt -297.4m / EBITDA 3.13b)
Debt / FCF = -0.12 (Net Debt -297.4m / FCF TTM 2.46b)
Total Stockholder Equity = 19.68b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.66% (Net Income 1.54b / Total Assets 34.58b)
RoE = 7.81% (Net Income TTM 1.54b / Total Stockholder Equity 19.68b)
RoCE = 5.66% (EBIT 1.63b / Capital Employed (Equity 19.68b + L.T.Debt 9.15b))
RoIC = 4.64% (NOPAT 1.31b / Invested Capital 28.21b)
WACC = 6.76% (E(39.96b)/V(49.41b) * Re(8.17%) + D(9.45b)/V(49.41b) * Rd(0.99%) * (1-Tc(0.20)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.47%
[DCF Debug] Terminal Value 84.38% ; FCFF base≈2.35b ; Y1≈2.69b ; Y5≈3.75b
Fair Price DCF = 803.6 (EV 85.37b - Net Debt -297.4m = Equity 85.67b / Shares 106.6m; r=6.76% [WACC]; 5y FCF grow 17.15% → 2.90% )
EPS Correlation: 97.55 | EPS CAGR: 9.01% | SUE: 2.67 | # QB: 6
Revenue Correlation: 99.73 | Revenue CAGR: 13.51% | SUE: -1.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.98 | Chg30d=-0.195 | Revisions Net=+1 | Analysts=16
EPS current Year (2026-12-31): EPS=21.47 | Chg30d=-0.200 | Revisions Net=-1 | Growth EPS=+7.4% | Growth Revenue=+7.8%
EPS next Year (2027-12-31): EPS=23.35 | Chg30d=-0.316 | Revisions Net=-1 | Growth EPS=+8.8% | Growth Revenue=+6.9%